Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Boston Scientific Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $64.5B | |
|---|---|---|
| Revenue (ttm) | 21.1B | |
| Net income (ttm) | 3.5B | |
| EPS (ttm) | $2.37 | |
| Shares out | 1.4B | |
| P/E (trailing) | 17.8x | |
| P/E (forward) | 13.2x | |
| Volume | 66,508,095 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B | +14.0% |
| Gross profit | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B | +14.1% |
| Operating income | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B | +31.8% |
| Net income | $1.04B | $698.0M | $1.59B | $1.85B | $2.89B | +29.1% |
| EPS (diluted) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | +29.5% |
| EBITDA | $2.52B | $2.74B | $3.45B | $3.94B | $5.10B | +19.3% |
| R&D | $1.20B | $1.32B | $1.41B | $1.62B | $2.05B | +14.3% |
| SG&A | $4.36B | $4.52B | $5.19B | $5.98B | $6.89B | +12.1% |
Recent company headlines from major financial publishers.
In the bull case, rapid clinical adoption of pulsed field ablation in international territories outpaces expectations, while FARAPULSE Ultra and ICE achieve broad commercial availability ahead of schedule in early 2027. Standalone WATCHMAN volume contraction reverses quickly as clinical education programs and 3-year CHAMPION trial data reassure physicians,. Annual diluted EPS growth reaches 14.5% to 15.0%, and operating margins expand toward top-tier peer levels.
The base case models management's updated FY2026 organic revenue guidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.0% | $73.0 | $75.7 | $78.6 | $82.0 | $85.9 |
| 7.5% | $67.2 | $69.3 | $71.6 | $74.2 | $77.1 |
| 8.0% | $62.5 | $64.1 | $65.9 | $68.0 | $70.2 |
| 8.5% | $58.5 | $59.8 | $61.3 | $62.9 | $64.7 |
| 9.0% | $55.1 | $56.2 | $57.4 | $58.7 | $60.1 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
